Natalizumab

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3778
R8084
Portaccio (control exposed to IFN), 2018 Cesarean delivery early pregnancy excluded prospective cohort unexposed, sick Adjustment: No 1.15 [0.57;2.31] C
excluded (exposition period)
26/54   34/76 60 54
ref
S3777
R8072
Portaccio (control unexposed, sick), 2018 Cesarean delivery early pregnancy prospective cohort unexposed, sick excluded Adjustment: No 1.13 [0.63;2.02] C
excluded (control group)
26/54   142/315 168 54
ref
S3770
R8061
Ebrahimi (control unexposed, disease free), 2015 Cesarean section (planned and emergency) 3 months or more before pregnancy or1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 2.31 [1.10;4.87] C
excluded (control group)
31/73   15/62 46 73
ref
S3769
R8054
Ebrahimi (control unexposed, sick), 2015 Cesarean section (planned and emergency) 3 months or more before pregnancy or1st trimester excluded prospective cohort unexposed, sick Adjustment: No 1.38 [0.69;2.74] C
excluded (exposition period)
31/73   23/66 54 73
ref
Total 0 studies NaN [NaN;NaN] 0 0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis